This research study is studying an investigational drug called EOC237 in Patients With Advanced Solid Tumor.

Part 1 Dose Escalation: an open, single/multiple dose, multi-center phase I study to evaluate the safety, tolerability and pharmacokinetics of EOC237 in Patients With Advanced Solid Tumor.

Part 2 Food influence research: to assess the effect of food on the pharmacokinetics of EOC237, by investigating the bioavailability following single dose administration under fed and fasted conditions.

Inclusion Criteria:

• Advanced Solid Tumors for which standard curative or palliative measures do not exist or are no longer effective.
• Expected survival≥ 3 months.
• ECOG performance status 0-1.
• Good organ and marrow function.

Exclusion Criteria:

• Patients with a history of severe drug allergic reaction.
• Pregnant or lactating female subjects.
• Uncontrolled, significant intercurrent or recent illness.
• Corrected QT interval calculated by the Fridericia formula (QTcF) > 480 ms per electrocardiogram (ECG)
• Concomitant use of certain medications